Completed PHASE2 INTERVENTIONAL 4-arm NCT00560300

Regulation of Bone Formation in Renal Osteodystrophy

Sponsor: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)

Conditions Renal Osteodystrophy Secondary Hyperparathyroidism

Interventions 1 alpha D2 1,25 dihydroxy vitamin D3 Calcium Carbonate Sevelamer HCl

Updated 5 times since 2017 Last updated: Jan 12, 2010 Started: Nov 30, 2000 Completion: Nov 30, 2006

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT00560300, this PHASE2 trial focuses on Renal Osteodystrophy and Secondary Hyperparathyroidism and remains completed. Sponsored by National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), it has been updated 5 times since 2000, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.

Status Flow

Change History

5 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE2
Jul 2024 — Sep 2024 [monthly]

Completed PHASE2
Jan 2021 — Jul 2024 [monthly]

Completed PHASE2
Jun 2018 — Jan 2021 [monthly]

Completed PHASE2
Jan 2017 — Jun 2018 [monthly]

Completed PHASE2

First recorded

Nov 2000

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)

Data source: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

No location information available.